Methylphenidate Hydrochloride
Brand Names: Metadate Cd, Relexxii, Ritalin LA, Ritalin, Quillichew ER, Methylin
Methodology & AI Transparency ⓘ
Methylphenidate Hydrochloride Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Indications and usage: Attention Deficit Disorders, Narcolepsy Attention Deficit Disorders (previously known as Minimal Brain Dysfunction in Children).
- 2 Real-world patient consensus: Tracked across 21 patient dosage logs with a 83% satisfaction benchmark (RxCUI 1091133).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $185.00 cash mean against $453.25 retail pharmacy pricing.
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Methylphenidate Hydrochloride: nausea (12%), headache (10.6%), dizziness (6.3%).
Ask our AI Specialists anything about Methylphenidate Hydrochloride
Methylphenidate Hydrochloride Mechanism, CYP450 Pathways & DailyMed Monograph
Indications and usage: Attention Deficit Disorders, Narcolepsy Attention Deficit Disorders (previously known as Minimal Brain Dysfunction in Children). Other terms being used to describe the behavioral syndrome below include: Hyperkinetic Child Syndrome, Minimal Brain Damage, Minimal Cerebral Dysfunction, Minor Cerebral Dysfunction.
CLINICAL PHARMACOLOGY Methylphenidate is a racemic mixture comprised of the d- and l-threo enantiomers. The d-threo enantiomer is more pharmacologically active than the l-threo enantiomer. Methylphenidate HCl is a central nervous system (CNS) stimulant. The mode of therapeutic action in humans is not completely understood, but methylphenidate presumably activates the brain stem arousal system and cortex to produce its stimulant effect. Methylphenidate is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.
With Approximately 6–19 hours terminal plasma half-life for Methylphenidate Hydrochloride residence kinetics and Estimated 54%–66% oral systemic absorption for Methylphenidate Hydrochloride bioavailability, Methylphenidate Hydrochloride undergoes phase i/ii hepatic conjugation of methylphenidate hydrochloride coupled with glomerular and tubular renal excretion and establishes therapeutic activity over peak plasma concentration (tmax) reached 1–4 hours post-dose for methylphenidate hydrochloride.
Standard adult regimens span 40 mg/1 Capsule, 80 mg/1 Capsule, 10 mg/5mL Solution, 36 mg/1 Tablet, Extended Release, 18 mg/1 Tablet, Extended Release. Prescribers screen specifically against contraindications marked anxiety, tension, and agitation are contraindications to methylphenidate hydrochloride, since the drug may aggravate these symptoms.; documented intolerance or hypersensitivity reaction involving methylphenidate hydrochloride (central nervous system stimulant), while community micro-logs most frequently note nausea (12% of reports), headache (10.6% of reports), somnolence (7% of reports).
Assess baseline hepatic panels and interacting prescriptions when starting Methylphenidate Hydrochloride (central nervous system stimulant).
Unstandardized herbal extracts may interact pharmacodynamically with Methylphenidate Hydrochloride maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- CONTRAINDICATIONS Marked anxiety, tension, and agitation are contraindications to methylphenidate hydrochloride, since the drug may aggravate these symptoms.
- Documented intolerance or hypersensitivity reaction involving Methylphenidate Hydrochloride (central nervous system stimulant)
Logged Side-Effect Incidence (21 Reports)
Methylphenidate Hydrochloride Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Methylphenidate Hydrochloride)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate The measurements used for the assessment of apathy in patients with AD had a high degree of overlap with the DCA. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry • 2021-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 32565008 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Trimodal Dexmethylphenidate (CTx-1301) in Children and CTx-1301 demonstrated dose-related improvements in signs and symptoms of ADHD, although statistical significance is not consistent across all dose groups. Journal of child and adolescent psychopharmacology • 2026-12-15 • Phase III Randomized Trial | N = 103 | 88/100 | PMID 42484049 ↗ |
| Can This Approach Help? Inside the Latest Research on A Randomized, Phase 3, gold-standard blind, Crossover Comparison of Multilayer, PRC-063 and LDX had comparable effects on driving performance, from 1 through 15 hours, the last time point measured. Journal of attention disorders • 2024-04-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38404033 ↗ |
| Can This Approach Help? Inside the Latest Research on A Post-Hoc Analysis of Emotional Lability With Delayed-Release/Extended-Release DR/ER-MPH treatment resulted in statistically significant improvements in EL to the level of non-ADHD peers as contextualized by T -scores. Journal of attention disorders • 2024-06-15 • Phase III Randomized Trial | N = 117 | 88/100 | PMID 38600754 ↗ |
| Can This Approach Help? Inside the Latest Research on Symptomatic and Functional Response and full symptom relief From the Open-Label More participants starting on a 40-mg versus 20-mg dose achieved thresholds at week 1 ( P Conclusions: When DR/ER-MPH dosing was optimized for ADHD symptom control throughout the. The Journal of clinical psychiatry • 2021-06-22 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34166587 ↗ |
Methylphenidate Hydrochloride Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $14.9660/unit (~$448.98/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 21 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Methylphenidate Hydrochloride Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Methylphenidate Hydrochloride RxNorm Concept ID | 1091133 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $14.9660 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 83.00% Worth It (21 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Methylphenidate Hydrochloride Patient Community, Cohort Filters & Dosage Logs
Cross-verified Methylphenidate Hydrochloride (central nervous system stimulant) monograph synthesizing RxNorm 1091133, openFDA FAERS signals, and $185.00–$453.25 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Methylphenidate Hydrochloride community threads and patient logs by age, biological sex, dosage, and treatment duration.